In the current real-world study, we found a trend towards an increased risk of heart failure and CV events in women treated with aromatase inhibitors, a pure anti-estrogen agent, as compared to those treated with tamoxifen, an agonist/antagonist estrogen drug with possibly cardioprotective activity [22,23,24]. This evidence concerns the gene CYP19A1 and heart failure.